A single bolus of high dose levothyroxine (L-T\textsubscript{4}) as a test in cases of suspected poor compliance to L-T\textsubscript{4} therapy

Krzysztof C. Lewandowski\textsuperscript{1,2}, Katarzyna Dąbrowska\textsuperscript{1}, Iwona Komorowska-Dudek\textsuperscript{1} and Andrzej Lewiński\textsuperscript{1,2*}

Abstract

**Background:** Though compliance (or adherence) problems, as well as inappropriate levothyroxine (L-T\textsubscript{4}) intake (e.g. with meal, other drugs or certain foods that can significantly affect absorption) are very common, the issue is often either not mentioned or even frankly denied by patients.

**Case Presentation:** We describe three cases of patients who presented with high TSH (ranging from about 30 to 200 mIU/l), with concomitantly either high, normal or low free thyroxine (FT\textsubscript{4}), despite treatment with high doses of L-T\textsubscript{4}. The above mentioned problems with adjustment of L-T\textsubscript{4} dose persisted for several months or even years. Coeliac disease screen was negative in all cases.

In all these patients administration of a single bolus of L-T\textsubscript{4} (1000 μg) or two doses of 1000 μg of L-T\textsubscript{4} within 48 h resulted in a quick increase in FT\textsubscript{4} (thus confirming proper absorption) and in normalization of TSH within a week.

**Conclusions:** Our data support the efficacy, as well as safety of administration of single bolus of high dose L-T\textsubscript{4} as a test for possible compliance/adherence problems.

**Key words:** Levothyroxine, Adherence, Compliance

Background

Compliance (also termed adherence) problems, as well as inappropriate intake of levothyroxine (L-T\textsubscript{4}) (e.g. with meal, other drugs or certain foods that affect absorption) are considered to be very common, yet, the issue is typically either not mentioned, or even denied by patients. Precise incidence of compliance problems is not known, but may be quite high. For instance, Morris et al. [1] report that about 40 % of 74 pediatric patients (median age 12.5 years) had at least one episode of non-compliance following thyroidectomy. Here we present three cases, where suspected poor compliance was confirmed by a high dose L-T\textsubscript{4} test.

**Patient I**

A 22-year old male after thyroidectomy (BMI 26.1 kg/m\textsuperscript{2}) for poorly controlled Graves’ disease, complicated by recurrent laryngeal nerve palsy and hypocalcaemia (post-surgical hypoparathyroidism) presented with high TSH and high free thyroxine (FT\textsubscript{4}) despite 150 μg of L-T\textsubscript{4} daily (Table 1). A possibility of poor compliance to medication was raised, particularly in view of episodes of concomitantly high TSH and high FT\textsubscript{4} (Table 1). He was admitted to hospital, where 1000 μg of L-T\textsubscript{4} was administered without any side-effects. This was followed by normalization of TSH and FT\textsubscript{4} (Table 2). Subsequently, he has never turned up for any future follow-up.

**Patient II**

Twenty-one year old female (weight about 55 kg, BMI 21.2 kg/m\textsuperscript{2}) presented with very high TSH (198.76 μIU/ml during hospital admission, previous TSH in the outpatient setting 378 μIU/ml) despite taking 175 μg of L-T\textsubscript{4}. Problems with adequate control dated back about 6 years with massive swings in TSH concentrations (e.g. TSH 92.58 μIU/ml and 23.3 on 200 μg of L-T\textsubscript{4}, and 2 years later TSH 0.062 μIU/ml on 150 μg of L-T\textsubscript{4}). Dilution test (Table 3) showed no evidence of interference.
with similar post-dilution recovery concentrations. Levothyroxine (1000 µg) was administered with quick reduction of TSH and evidence of good absorption of L-T₄ (a rise in FT₄ from 1.13 ng/dl to 2.72 ng/dl within 10 h) - Table 4. She eventually admitted to missing occasional tablets and more often to taking L-T₄ with or even after breakfast with morning coffee. About 2 months post discharge she presented with suppressed TSH. The dose of L-T₄ was gradually decreased to 125 µg/day.

Patient III
Fifty-eight year old obese woman (BMI about 35 kg/m²) presented with high TSH and low FT₄ despite taking high dose of L-T₄ (300 µg/day). She had a history of thyroidectomy for Graves’s disease about 3 years before, and according to documentation she was rather erratic in taking her methimazole tablets, that was one of the reasons to proceed with thyroid surgery. She also had a history of cholecystectomy for cholelithiasis and was waiting for appointment with gastroenterologists because of abnormal liver function tests (Table 5). She was taking Calcium and vitamin D preparations for osteoporosis prophylaxis. She denied excessive alcohol consumption. Two doses of 1000 µg of L-T₄ were administered within 48 h without any adverse effects. This was followed by marked improvement of her well-being, as well as her thyroid function tests results (Table 6). She was told that it was essential to take her L-T₄ tablets at least 60 min before breakfast (that she had not done before). Two months post discharge she had a low-normal FT₄ [0.97 ng/dl (referenced range 0.93–1.70)] and slightly raised TSH [12.06 mIU/l (reference range 0.27–4.20)]. She did not turn up for her follow-up appointment scheduled 1 week after her blood test.

**Discussion**
Our cases demonstrate that administration of a single high dose of L-T₄ can be useful in cases of suspected poor compliance. Due to a relatively long half-life of L-T₄ an idea of once-weekly administration regimen had been raised before and tested with a considerable success [2, 3], where single doses of L-T₄ oscillated around 1000–1500 µg. Though administration of such high dose of L-T₄ might be thought to be potentially associated with side-effects, such as heart palpitations, angina, etc., the test was reported to be surprisingly well tolerated [4–6]. Furthermore, some patients actually preferred a weekly, rather than a daily L-T₄ administration [4, 6]. In accordance with these data we did not observe any adverse effects of administration of these high doses of L-T₄, while some authors (KCL) participated in a study where even a higher dose of L-T₄ (2000 µg) was administered without any side-effects, while testing for heterophilic antibodies interference [7]. According to the literature data, the upper range of age of patients tested for possible non-adherence with high dose L-T₄ was as high as 88 years [6]. Also current FDA bioequivalence

| Table 1 Thyroid function tests of 22-year old male prior to L-T₄ test |
|---|
| **Date** | TSH (mIU/ml) | Reference range (mIU/ml) | FT₄ (ng/dl) | Reference range (ng/dl) | Free triiodothyronine (FT₃) (pg/ml) | Reference range (pg/ml) |
| 06.01 | <0.005⁶ | 0.27–4.2 | 1.21⁵ | 0.93–1.7 | 7.35 | 2.6–4.4 |
| 18.03 | - | 0.27–4.2 | 2.11 | 0.93–1.7 | 9.28 | 2.6–4.4 |
| 10.05 | - | 0.27–4.2 | 0.583⁵ | 0.93–1.7 | 3.98 | 2.6–4.4 |
| 17.06⁶ | 80.74 | 0.27–4.2 | - | 0.93–1.7 | - | 2.6–4.4 |
| 06.09 | 15.77 | 0.27–4.2 | 1.74 | 0.93–1.7 | - | 2.6–4.4 |
| 23.09 | 19.22 | 0.27–4.2 | - | 0.93–1.7 | - | 2.6–4.4 |
| 03.11 | 27.84 | 0.27–4.2 | 1.42 | 0.93–1.7 | - | 2.6–4.4 |
| 10.11 | 14.53 | 0.27–4.2 | 1.93 | 0.93–1.7 | 3.99 | 2.6–4.4 |

⁶results after thyroidectomy in June 2010

| Table 2 1000 µg L-T₄ test in Patient I |
|---|
| **Date** | TSH (mIU/ml) | Reference range (mIU/ml) | FT₄ (ng/dl) | Reference range (ng/dl) | FT₃ (pg/ml) | Reference range (pg/ml) |
| Day 0⁶ | 18.92 | 0.27–4.2 | 1.54 | 0.93–1.7 | 3.06 | 2.6–4.4 |
| Day 1 | 8.79 | 0.27–4.2 | 4.32 | 0.93–1.7 | 4.69 | 2.6–4.4 |
| Day 2 | 6.87 | 0.27–4.2 | 3.36 | 0.93–1.7 | 4.69 | 2.6–4.4 |
| Day 3 | 2.34 | 0.27–4.2 | 2.58 | 0.93–1.7 | 4.26 | 2.6–4.4 |
| Day 4 | 1.40 | 0.27–4.2 | 2.22 | 0.93–1.7 | 3.84 | 2.6–4.4 |
| Day 5 | 1.16 | 0.27–4.2 | 1.82 | 0.93–1.7 | 4.93 | 2.6–4.4 |
| Day 6 | 2.76 | 0.27–4.2 | 1.65 | 0.93–1.7 | 3.45 | 2.6–4.4 |

⁶received 1000 µg of L-T₄ (Euthyrox N°) as a single fasting dose
guidelines require that supra-therapeutic doses of L-T₄ (around 600 µg) should be administered in studies aiming to assess pharmacokinetics of L-T₄ preparations [8]. One must be, however, aware that despite an excellent tolerance data, the number of patients participating in weekly L-T₄ studies was still relatively small (e.g. 12 patients in 3, or 23 patients in 6), so that a caution must be applied in case of patients with a history of active ischaemic heart disease (e.g. confirmed unstable angina, after coronary artery by-pass grafts, etc.).

Another issue pertains to the very definition of non-compliance or non-adherence. In case of L-T₄, this may involve both missing tablets completely (most likely in Patient I), or taking them tablets inappropriately, e.g. with meal or after meal with concomitant ingestion of coffee, etc. (Patients II and III). For instance, Bach-Huynh et al. [9] demonstrated that even with full compliance, an ingestion of L-T₄ tablets within 20 min of breakfast results in more than 100 % increase in mean TSH concentrations (1.54 mIU/l versus 3.74 mIU/l), as well as a dispersion of measured TSH values up to around 19 mIU/l. Though in a seminal study of Wenzel and Kirschsieper [10] ingestion of L-T₄ was reduced down to 64 % (for a 100 µg dose), if taken with food, even lower values (down to 40 %) are quoted [8]. Certain food and drinks affect absorption of L-T₄. In particular this includes dietary fibres (e.g. in muesli, corn-flakes), coffee, grapes, soybeans and papaya fruits [11], of which the first two are commonly consumed with breakfast in Poland. Calcium salts, currently commonly combined with vitamin D, as a part of osteoporosis prophylaxis, and often taken with food during breakfast (applicable in our Patient III), can also significantly impair L-T₄ absorption [12]. Absorption of L-T₄ is also decreased in cases of higher gastric pH, such as atrophic gastritis, use of proton pump inhibitors, as well as Helicobacter pylori infection [8, 11]. Intestinal, as well as hepatic diseases are associated with worse absorption of L-T₄. This might be relevant to our Patient III, as she had previous cholecystectomy, abnormal liver function tests and was taking Calcium and vitamin D preparations for osteoporosis prophylaxis. She was referred for gastroenterological consultation with view of performing an endoscopic retrograde cholangiopancreatography (ERCP). There is also a well known phenomenon of enterohepatic circulation of thyroid hormones [13], that was also therapeutically explored for instance for treatment of thyrotoxicosis in humans [14, 15]. In particular, biliary disease might have potentially influenced reabsorption of thyroid hormones, particularly in a hypothyroid state, as there are data [13] that hypothyroid rats had diminished levels of bile acid synthesis and biliary secretion of cholesterol and phospholipid. In such settings, a single dose triiodothyronine (T₃) injection produced a 13-fold increase in bile cholesterol secretion and a 3-fold increase in phospholipid secretion, both initiated 12 h after T₃ administration [13]. It should mentioned, however, that though unresolved issue of abnormal liver function might have contributed to a decrease of L-T₄ absorption in Patient III, it was unlikely to be a sole factor responsible for clinical picture observed in this patient. This is because of a striking increase of FT₄ concentrations (from 0.36 ng/dl, to 1.18 ng/dl) at about 10 h post ingestion of 1000 µg of L-T₄ (on an empty stomach with breakfast delayed to 60 min post ingestion). This confirms an adequate absorption of L-T₄ tablets on condition that they were swallowed in an appropriate fashion. Indeed Walker et al. [6] studied absorption of L-T₄ (once a week, dose calculated as 1.6 µg/kg per day and

| Table 3 | Serial dilution test of 21 year old female with very high TSH |
| Date | TSH (µIU/ml) | Dilution 4x | Dilution 8x | Dilution 16x | Dilution 32x |
|-----|--------------|-------------|-------------|-------------|-------------|
| Day 0 | >100 | 198.76 (4 x 48.94) | 199.44 (8 x 24.93) | 209.8 | 221.12 |
| Recovery: | (16 x 13.11) | (32 x 6.91) |
| 100.3 % | Recovery: | Recovery: |
| (199.44 x 100 %/198.76) | 105.5 % | 111.2 % |

*received 1000 µg of L-T₄ (Euthyrox N®) as a single fasting dose

| Table 4 | 1000 µg L-T₄ test in Patient II |
| Date | TSH (µIU/ml) | Reference range (µIU/ml) | FT₄ (ng/dl) | Reference range (ng/dl) | FT₃ (pg/ml) | Reference range (pg/ml) |
|-----|--------------|--------------------------|-------------|--------------------------|-------------|--------------------------|
| Day 0 | >100 | 0.27–4.2 | 1.13 | 0.93–1.7 | 2.01 | 2.6–4.4 |
| Day 0* (6:00 PM) | 37.91 | 0.27–4.2 | 2.72 | 0.93–1.7 | 2.10 | 2.6–4.4 |
| Day 1 | 25.54 | 0.27–4.2 | 1.99 | 0.93–1.7 | 2.96 | 2.6–4.4 |
| Day 2 | 10.37 | 0.27–4.2 | 1.82 | 0.93–1.7 | 3.22 | 2.6–4.4 |
| Day 3 | 7.82 | 0.27–4.2 | 1.58 | 0.93–1.7 | 3.09 | 2.6–4.4 |

*received 1000 µg of L-T₄ (Euthyrox N®) as a single fasting dose

| Table 5 | Liver function of 58-year old women with high TSH on 300 µg of L-T₄ |
| Liver function tests | Result (IU/l) | Reference range (IU/l) |
|----------------------|--------------|------------------------|
| ASPAT | 182.00 | 14–36 |
| ALAT | 102.00 | 9–52 |
| GGTP | 452.00 | 12–43 |
| Alkaline phosphatase | 87 | 38–126 |
Table 6 High dose L-T₄ test in Patient III (1000 μg twice within 48 h)

| Day 0* (8.00 AM) | TSH (μIU/ml) | Reference range (μIU/ml) | FT₄ (ng/dl) | Reference range (ng/dl) | FT₃ (pg/ml) | Reference range (pg/ml) |
|------------------|--------------|--------------------------|-----------|----------------------|------------|----------------------|
| Day 0 (6.00 PM)  | 20.37        | 0.27–4.2                 | 1.18      | 0.93–1.7             | 1.56       | 2.6–4.4              |
| Day 1            | 17.43        | 0.27–4.2                 | 1.08      | 0.93–1.7             | 1.72       | 2.6–4.4              |
| Day 2* (8.00 AM) | 15.69        | 0.27–4.2                 | 2.08      | 0.93–1.7             | 1.98       | 2.6–4.4              |
| Day 3            | 11.54        | 0.27–4.2                 | 1.71      | 0.93–1.7             | 2.34       | 2.6–4.4              |
| Day 4            | 12.60        | 0.27–4.2                 | 1.58      | 0.93–1.7             | 2.31       | 2.6–4.4              |
| Day 5            | 8.50         | 0.27–4.2                 | 1.46      | 0.93–1.7             | 2.21       | 2.6–4.4              |

* received 1000 μg of L-T₄ (Euthyrox N®) as a single fasting dose

given as a single weekend dose) at 60, 120, 180 and 240 min after L-T₄ bolus, and concluded that in 82% of cases the maximal rise of FT₄ occurred as soon as at 120 min. Hence, there is a possibility that in patient FT₄ concentrations might be even higher if tested at an earlier timing. It might be also interesting to mention, that Australian authors [16] proposed a variation of L-T₄ absorption test that involves co-administration of paracetamol tablets for detection of cases of deliberate avoidance of tablet swallowing.

Conclusions

In summary, our data support the efficacy, as well as safety of administration of single bolus of high dose L-T₄ in some patients who fail to normalize their thyroid function tests, despite prolonged attempts to adjust their L-T₄ dose in the outpatient settings. To the best of our knowledge this is the first paper in Polish medical literature describing clinical application of bolus high dose L-T₄ test for possible non-compliance problems.

Consent

Written informed consent was obtained from the patients for publication of this case report. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Competing interests

All authors declare that they have no competing interests.

Authors’ contributions

KCL, KD, IK-D and AL - clinical management, acquisition of data and preparation of the manuscript. All authors read and approved the final manuscript.

Acknowledgments

This study was supported by statutory funds from the Department of Endocrinology and Metabolic Diseases, Polish Mother’s Memorial Hospital—Research Institute, Lodz, Poland.

Received: 26 October 2015 Accepted: 24 November 2015
Published online: 01 December 2015

References

1. Moins LF, Waguespack SG, Warneke CL, Ryu H, Ying AK, Anderson BJ, et al. Long-term follow-up data may help manage patient and parent expectations for pediatric patients undergoing thyroidectomy. Surgery. 2012;152:1165–71.
2. Them-Wai W, Larsen PR. Effects of weekly thyroxine administration on serum thyroid hormone, 3,3',5'-triiodothyronine, thyrotropin, and the thyrotropin response to thyrotropin-releasing hormone. J Clin Endocrinol Metab. 1980;50:560–4.
3. Grebe SKG, Cooke RR, Ford HC, Fagerstrom JN, Cordwell DP, Lever NA, et al. Treatment of hypothyroidism with once weekly thyroxine. J Clin Endocrinol Metab. 1997;82:870–5.
4. Moisey R, Swinburne J, Omre S. Assessment and management of non-compliant hypothyroid patients: the role of weekly observed thyroxine therapy. Endocr Rev. 2007;13:358.
5. Elmahi E, Vas P, Oyibo S. Levothyroxine absorption test: a 5-day (usual dose) as an alternative to to the 1-day (1000 μg) test. Endocrine Abstr. 2013;31:P372.
6. Walker RN, Shillo P, Ibbotson V, Vincent A, Karavitaki N, Weetman AP, et al. A thyroxine absorption test followed by weekly thyroxine administration: a method to assess non-adherence to treatment. Eur J Endocrinol. 2013;168:913–7.
7. Ismail AAA, Walker PN, Barth JH, Lewandowski KC, Jones R, Burr WA. Wrong biochemistry results: two case reports and observational study in 5310 patients on potentially misleading thyroid-stimulating hormone and gonadotropin immunoassay results. Clin Chem. 2002;48:2023–9.
8. Colucci P, Seng Yue C, Ducharme M, Benvenga S. A review of the pharmacokinetics of levothyroxine for the treatment of hypothyroidism. Eur J Endocrinol. 2013;169:40–7.
9. Bach-Huynh T-G, Nayak B, Loh J, Saldin S, Jonklaas J. Timing of levothyroxine administration affects serum thyrotropin concentrations. J Clin Endocrinol Metab. 2009;94:3905–12.
10. Wenzel KW, Kirschiespe HE. Aspects of the absorption of oral L-thyroxine in normal man. Metabolism. 1977;30:798–9.
11. Ianiro G, Mangiola F, Di Renzo TA, Bibbo S, Franceschi F, Greco AV, et al. Levothyroxine absorption in health and disease, and new therapeutic perspectives. Eur Rev Med Pharmacol Sci. 2014;18:451–6.
12. Zamfirescu I, Carlson HE. Absorption of levothyroxine when coadministered with various calcium formulation. Thyroid. 2011;21:483–6.
13. Gehard RL, Prigge WF. Thyroid hormone differentially augments biliary sterol secretion in the rat. The chronic bile fistula model. J Lipid Res. 1992;33:1467–73.
14. Solomon BL, Wartofsky L, Burman KD. Adjunctive cholestyramine therapy for thyrotoxicosis. Clin Endocrinol (Oxf). 1993;38:39–43.
15. Tsai WC, Pei D, Wang TF, Wu DA, Li JC, Wei CL, et al. The effect of combination therapy with propylthiouracil and cholestyramine in the treatment of Graves’ hyperthyroidism. Clin Endocrinol (Oxf). 2005;62:251–24.
16. Thynne TRJ, Dooque MP. A dose of paracetamol for the levothyroxine absorption test. Clin Endocrinol (Oxf). 2013;78:986–9.